{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:15:39Z","timestamp":1783764939314,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["CAIN457FUS02T"],"award-info":[{"award-number":["CAIN457FUS02T"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Participants with active AxSpA beginning secukinumab with moderate disease activity had improvements in symptoms, but no substantial change in BMD and microarchitecture. Larger, longer-term controlled studies are needed to assess the impact of IL-17 blockade on skeletal health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Axial Spondyloarthritis (AxSpA) is linked to poor skeletal health, but whether IL-17 blockade, effective for symptom improvement, improves skeletal health is unknown. We investigated the impact of secukinumab on skeletal features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We prospectively enrolled AxSpA patients beginning therapy with secukinumab and followed them for 24\u00a0months. Clinical assessments, serum bone turnover markers, and cervical and lumbar spine radiographs were obtained. Areal BMD (aBMD) and trabecular bone score (TBS) measured by dual energy x-ray absorptiometry (DXA, spine, hip, forearm), volumetric BMD (vBMD), and microarchitecture measured by high-resolution peripheral quantitative computed tomography (HR-pQCT, Xtreme CT2, at the tibia and radius) were performed annually. DXA and HR-pQCT assessments were compared to reference cohorts of sex- and age-matched individuals. Changes were assessed through Wilcoxon and paired\n                      <jats:italic>t<\/jats:italic>\n                      -tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty AxSpA participants were enrolled, 50% female (13% postmenopausal) and 47% HLA-B27 positive. Mean symptom duration was 12\u00a0years, with moderate activity (BASDAI mean 5 [SD\u2009=\u20092]). Baseline DXA and HR-pQCT Z-scores were within 1 standard deviation of sex- and age-matched controls. BASDAI (\u2212\u200933%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and BASMI (\u2212\u200922%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) improved, but there was no improvement in aBMD, TBS, or microarchitecture. By HR-pQCT, vBMD decreased (\u2212\u20090.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), and cortical porosity increased (8.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). New vertebral fractures were not observed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-025-01565-w","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T10:35:29Z","timestamp":1749292529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axial spondyloarthritis using HR-pQCT"],"prefix":"10.1007","volume":"20","author":[{"given":"Chloe","family":"Heiting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas N.","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalit","family":"Ashany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insa","family":"Mannstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"1","key":"1565_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semarthrit.2017.12.001","volume":"48","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez J, Nieto-Gonz\u00e1lez JC, Curbelo Rodr\u00edguez R, Casta\u00f1eda S, Carmona L (2018) Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48(1):44\u201352. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.12.001","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"1565_CR2","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3899\/jrheum.100363","volume":"37","author":"RJ Weiss","year":"2010","unstructured":"Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases \u2013 a case-control study with 53,108 patients with fracture. J Rheumatol 37(11):2247\u20132250. https:\/\/doi.org\/10.3899\/jrheum.100363","journal-title":"J Rheumatol"},{"issue":"12","key":"1565_CR3","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/acr.25166","volume":"75","author":"S Merjanah","year":"2023","unstructured":"Merjanah S, Liew JW, Bihn J et al (2023) Trends in fracture rates over two decades among veterans with ankylosing spondylitis. Arthritis Care Res (Hoboken) 75(12):2481\u20132488. https:\/\/doi.org\/10.1002\/acr.25166","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1565_CR4","doi-asserted-by":"publisher","first-page":"e002753","DOI":"10.1136\/rmdopen-2022-002753","volume":"9","author":"K Bengtsson","year":"2023","unstructured":"Bengtsson K, Askling J, Lorentzon M et al (2023) Occurrence and relative risks for non-vertebral fractures in patients with ankylosing spondylitis compared with the general population: a register-based study from Sweden. RMD Open 9(1):e002753. https:\/\/doi.org\/10.1136\/rmdopen-2022-002753","journal-title":"RMD Open"},{"issue":"8","key":"1565_CR5","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/art.42120","volume":"74","author":"S Tan","year":"2022","unstructured":"Tan S, Bagheri H, Lee D et al (2022) Vertebral bone mineral density, vertebral strength, and syndesmophyte growth in ankylosing spondylitis: the importance of bridging. Arthritis Rheumatol 74(8):1352\u20131362. https:\/\/doi.org\/10.1002\/art.42120","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1565_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40279-013-0100-7","volume":"44","author":"H Fonseca","year":"2014","unstructured":"Fonseca H, Moreira-Gon\u00e7alves D, Coriolano HJA, Duarte JA (2014) Bone quality: the determinants of bone strength and fragility. Sports Med 44(1):37\u201353. https:\/\/doi.org\/10.1007\/s40279-013-0100-7","journal-title":"Sports Med"},{"key":"1565_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2019.01.024","volume":"122","author":"VF Caparbo","year":"2019","unstructured":"Caparbo VF, Furlam P, Saad CGS et al (2019) Assessing bone impairment in ankylosing spondylitis (AS) using the trabecular bone score (TBS) and high-resolution peripheral quantitative computed tomography (HR-pQCT). Bone 122:8\u201313. https:\/\/doi.org\/10.1016\/j.bone.2019.01.024","journal-title":"Bone"},{"issue":"10","key":"1565_CR8","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s00198-016-3621-8","volume":"27","author":"S Agarwal","year":"2016","unstructured":"Agarwal S, Rosete F, Zhang C et al (2016) In vivo assessment of bone structure and estimated bone strength by first- and second-generation HR-pQCT. Osteoporos Int 27(10):2955\u20132966. https:\/\/doi.org\/10.1007\/s00198-016-3621-8","journal-title":"Osteoporos Int"},{"key":"1565_CR9","doi-asserted-by":"crossref","unstructured":"Russell LA, Mannstadt I, Ashany D, et al. Disease activity and bone microarchitectural phenotype in patients with axial spondyloarthritis. HSS J Published online In press, accepted 2024","DOI":"10.1177\/15563316241268001"},{"issue":"26","key":"1565_CR10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J et al (2015) Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"issue":"6","key":"1565_CR11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070\u20131077. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209730","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1565_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1186\/s12891-021-04930-1","volume":"22","author":"J Braun","year":"2021","unstructured":"Braun J, Buehring B, Baraliakos X et al (2021) Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1. BMC Musculoskelet Disord 22(1):1037. https:\/\/doi.org\/10.1186\/s12891-021-04930-1","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"1565_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semarthrit.2014.05.008","volume":"44","author":"NN Haroon","year":"2014","unstructured":"Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM (2014) Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum 44(2):155\u2013161. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.008","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"1565_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/jbmr.3684","volume":"34","author":"KJ Beek","year":"2019","unstructured":"Beek KJ, Rusman T, van der Weijden MAC et al (2019) Long-term treatment with TNF-alpha inhibitors improves bone mineral density but not vertebral fracture progression in ankylosing spondylitis. J Bone Miner Res 34(6):1041\u20131048. https:\/\/doi.org\/10.1002\/jbmr.3684","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1565_CR15","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RGW Lambert","year":"2016","unstructured":"Lambert RGW, Bakker PAC, van der Heijde D et al (2016) Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 75(11):1958\u20131963. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208642","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1565_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/02841850902914099","volume":"50","author":"M Geijer","year":"2009","unstructured":"Geijer M, Gadeholt G\u00f6thlin G, G\u00f6thlin JH (2009) The validity of the New York radiological grading criteria in diagnosing sacroiliitis by computed tomography. Acta Radiol 50(6):664\u2013673. https:\/\/doi.org\/10.1080\/02841850902914099","journal-title":"Acta Radiol"},{"issue":"2","key":"1565_CR17","first-page":"107","volume":"43","author":"WCG Peh","year":"2002","unstructured":"Peh WCG (2002) Clinics in diagnostic imaging (70) Bilateral sacroiliitis due to ankylosing spondylitis. Singapore Med J 43(2):107\u2013111","journal-title":"Singapore Med J"},{"issue":"1","key":"1565_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18\u201324. https:\/\/doi.org\/10.1136\/ard.2008.094870","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1565_CR19","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281\u20132285","journal-title":"J Rheumatol"},{"issue":"12","key":"1565_CR20","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"8","key":"1565_CR21","first-page":"1609","volume":"22","author":"SD Jones","year":"1995","unstructured":"Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A (1995) A new scoring system for the bath ankylosing spondylitis metrology index (BASMI). J Rheumatol 22(8):1609","journal-title":"J Rheumatol"},{"issue":"4","key":"1565_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bone.2007.07.007","volume":"41","author":"HR Buie","year":"2007","unstructured":"Buie HR, Campbell GM, Klinck RJ, MacNeil JA, Boyd SK (2007) Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis. Bone 41(4):505\u2013515. https:\/\/doi.org\/10.1016\/j.bone.2007.07.007","journal-title":"Bone"},{"issue":"11","key":"1565_CR23","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/jbmr.4114","volume":"35","author":"DE Whittier","year":"2020","unstructured":"Whittier DE, Burt LA, Hanley DA, Boyd SK (2020) Sex- and site-specific reference data for bone microarchitecture in adults measured using second-generation HR-pQCT. J Bone Miner Res 35(11):2151\u20132158. https:\/\/doi.org\/10.1002\/jbmr.4114","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1565_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/rheumatology\/key128","volume":"58","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Braun J, Deodhar A et al (2019) Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology (Oxford) 58(3):388\u2013400. https:\/\/doi.org\/10.1093\/rheumatology\/key128","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1565_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2015","unstructured":"Creemers MC, Franssen MJ, Van\u2019t Hof MA, Gribnau FW, Van De Putte LB, Van Riel PL (2015) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64(1):127\u2013129. https:\/\/doi.org\/10.1136\/ard.2004.020503","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1565_CR26","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1565_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/jcph.876","volume":"57","author":"G Bruin","year":"2017","unstructured":"Bruin G, Loesche C, Nyirady J, Sander O (2017) Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol 57(7):876\u2013885. https:\/\/doi.org\/10.1002\/jcph.876","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1565_CR28","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL et al (2016) Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68(12):2901\u20132910. https:\/\/doi.org\/10.1002\/art.39805","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1565_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00198-021-06049-4","volume":"33","author":"A Deminger","year":"2022","unstructured":"Deminger A, Klingberg E, Lorentzon M et al (2022) Factors associated with changes in volumetric bone mineral density and cortical area in men with ankylosing spondylitis: a 5-year prospective study using HRpQCT. Osteoporos Int 33(1):205\u2013216. https:\/\/doi.org\/10.1007\/s00198-021-06049-4","journal-title":"Osteoporos Int"},{"issue":"1","key":"1565_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13075-017-1480-0","volume":"19","author":"A Deminger","year":"2017","unstructured":"Deminger A, Klingberg E, Lorentzon M et al (2017) Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. Arthritis Res Ther 19(1):273. https:\/\/doi.org\/10.1186\/s13075-017-1480-0","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1565_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/jbmr\/zjae068","volume":"39","author":"M Schini","year":"2024","unstructured":"Schini M, Vilaca T, Lui LY et al (2024) Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project. J Bone Miner Res 39(7):867\u2013876. https:\/\/doi.org\/10.1093\/jbmr\/zjae068","journal-title":"J Bone Miner Res"},{"key":"1565_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jbiomech.2017.05.011","volume":"59","author":"A Kroker","year":"2017","unstructured":"Kroker A, Plett R, Nishiyama KK, McErlain DD, Sandino C, Boyd SK (2017) Distal skeletal tibia assessed by HR-pQCT is highly correlated with femoral and lumbar vertebra failure loads. J Biomech 59:43\u201349. https:\/\/doi.org\/10.1016\/j.jbiomech.2017.05.011","journal-title":"J Biomech"},{"issue":"2","key":"1565_CR33","first-page":"191","volume":"34","author":"F Maas","year":"2016","unstructured":"Maas F, Spoorenberg A, Brouwer E et al (2016) Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-\u03b1 blocking therapy. Clin Exp Rheumatol 34(2):191\u2013199","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1565_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3899\/jrheum.150857","volume":"43","author":"MAC van der Weijden","year":"2016","unstructured":"van der Weijden MAC, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BAC, van der Horst-Bruinsma IE (2016) Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent vertebral fractures: results of a prospective observational cohort study. J Rheumatol 43(4):758\u2013764. https:\/\/doi.org\/10.3899\/jrheum.150857","journal-title":"J Rheumatol"},{"issue":"1","key":"1565_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0002-9440(10)62961-6","volume":"167","author":"MI Koenders","year":"2005","unstructured":"Koenders MI, Lubberts E, Oppers-Walgreen B et al (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167(1):141\u2013149","journal-title":"Am J Pathol"},{"issue":"12","key":"1565_CR36","doi-asserted-by":"publisher","first-page":"e0144655","DOI":"10.1371\/journal.pone.0144655","volume":"10","author":"IP Perpetuo","year":"2015","unstructured":"Perpetuo IP, Raposeiro R, Caetano-Lopes J et al (2015) Effect of tumor necrosis inhibitor therapy on osteoclasts precursors in ankylosing spondylitis. PLoS ONE 10(12):e0144655","journal-title":"PLoS ONE"},{"issue":"7957","key":"1565_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0140-6736(76)91504-X","volume":"1","author":"MA Khan","year":"1976","unstructured":"Khan MA, Kushner I, Braun WE (1976) Letter: Low incidence of HLA-B27 in American Blacks with spondyloarthropathies. Lancet 1(7957):483","journal-title":"Lancet"},{"issue":"5","key":"1565_CR38","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/art.33503","volume":"264","author":"JD Reveille","year":"2012","unstructured":"Reveille JD, Hirsch R, Dillon CF et al (2012) The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey. Arthritis Rheum 264(5):1407\u201311","journal-title":"Arthritis Rheum"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01565-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01565-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01565-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:17:54Z","timestamp":1766524674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01565-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01565-w","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were reviewed and approved by the Hospital for Special Surgery\u2019s Institutional Review Board (#2017\u20130660). Patients joined the study with an informed consent process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: WY, MD, declares a relationship with Novartis; SMG, MD, reports relationships with UCB and Novartis; EMS, MD, reports a relationship with Radius Pharmaceuticals. The other authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"73"}}